Cereno Scientific

Cereno Scientific is a Swedish clinical-stage biotech company developing epigenetic therapies for rare cardiovascular and pulmonary diseases. Its pipeline centers on HDAC-modulating programs, including CS1, CS014 and CS585, which are being advanced through preclinical and clinical development.

— Cereno Scientific
%
CS1 clinical program40% Development of CS1 for pulmonary arterial hypertension and related cardiopulmonary indications.
CS014 clinical program30% Development of CS014 through early clinical testing and Phase II preparation.
CS585 preclinical program20% Preclinical development of CS585, a selective prostacyclin receptor agonist.
Research, regulatory and partnering activities10% Translational research, regulatory work, and external partnering support across the pipeline.

Cereno Scientific does not sell commercial medicines today; its direct counterparties are regulators, clinical trial...

  • Patients with rare cardiopulmonary diseaseprimary

    Ultimately buy the therapeutic benefit through prescribed medicines for PAH and related indications.

  • Pharmaceutical licensing partnerssecondary

    May partner on later-stage assets that show differentiated clinical and regulatory progress.

  • Clinical research ecosystemsecondary

    CROs, investigators, and academic collaborators support trial execution and data generation.

  • Regulatorssecondary

    FDA and other agencies review trial design, safety, and development pathways.

Cereno Scientific is headquartered in Sweden and operates as a Nordic biotech with a global clinical and partnering...

  • •Sweden is the corporate base and main operating center
  • •United States is important for FDA interaction and clinical development
  • •Europe is a core region for scientific conferences and partnering
  • •Global partnering events support investor and licensing outreach
  • •Clinical work is outsourced and collaborative across multiple countries

Cereno Scientific’s strategy is to advance its HDAC-based pipeline through clinical milestones that reduce development...

01
Advance clinical milestones for CS1 and CS014short-term

Clinical data and trial progress are the main value drivers for a biotech without commercial revenue.

02
Strengthen regulatory positioningshort-term

Fast Track and similar designations can improve development efficiency and partnering appeal.

03
Build partnering optionalitymedium-term

Later-stage clinical assets may attract larger pharma partners or licensing discussions.

04
Develop the broader HDAC platformlong-term

Platform breadth can create multiple shots on goal across cardiopulmonary diseases.

The company’s value depends on successful clinical development, regulatory acceptance, and access to financing before...

critical

Clinical development failure

Pipeline value depends on positive safety, efficacy, and tolerability data in small patient populations.

Scope
CS1, CS014, CS585
Materiality
high
high

Financing and dilution risk

The company is pre-revenue and must fund multi-year trials and regulatory work.

Scope
Corporate funding runway
Materiality
high
high

Regulatory risk

Trial design, endpoints, and agency feedback can alter timelines and development costs.

Scope
FDA interactions and Phase II planning
Materiality
high
medium

Partnering and commercialization risk

Future value may depend on securing collaborations or licensing on favorable terms.

Scope
Business development
Materiality
medium
Research and development expense recognition
Quarterly and annual results can swing with study activity and external service spend
Convertible loans and warrants
Reported earnings and share count may be affected by conversion terms
Going-concern assessment
Disclosure and valuation depend on financing assumptions

Core Scientific, Inc./tx

CORZ · Finance Services

Ceribell, Inc.

CBLL · Electromedical & Electrotherapeutic Apparatus

Zeo ScientifiX, Inc.

ZEOX · Biological Products, (No Diagnostic Substances)

NEUROCRINE BIOSCIENCES INC

NBIX · Biological Products, (No Diagnostic Substances)

CellaVision

CEVI.ST · Health Care

Crinetics Pharmaceuticals, Inc.

CRNX · Pharmaceutical Preparations

: 11/08/2026